Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Prostatic Hyperplasia

Treatments: Drug: 5ARI or AB or Combination Therapy (5ARI + AB)

Study type: Observational

Funder types: Industry

Identifiers

NCT01390870

112597

Details and patient eligibility

About

Patient-based surveys will be conducted to evaluate the drivers of medication adherence in patients treated with either 5-alpha-reductase inhibitor (5ARI) therapy, alpha-blocker (AB) therapy, or combination therapy for enlarged prostate (EP). Adherence with EP therapy will be evaluated. The researchers believe that the majority of participants will report that they are compliant with therapy. The data source is a cross-sectional patient survey administered at one time point.

Enrollment: 400 patients

Sex: Male

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males
• Aged 50 years or older
• Residents of the United States
• Receiving a prescription for an enlarged prostate (EP) treatment within 12 months prior to survey initiation

Exclusion criteria

• Patients with prostate cancer
• no health/prescription insurance
• patients receiving medication(s) for EP on a PRN basis

Trial design

400 participants in 1 patient group

Patient Survey

Description:

Men from the United States aged 50 years or older who initiated medication for EP within the past 12 months.

Treatment:

Drug: 5ARI or AB or Combination Therapy (5ARI + AB)